New and emerging therapies such as biologics continue to improve quality of life and outcomes for patients with psoriasis. Biologics that block IL-23 functions present a unique opportunity to provide long-term, effective treatment.

A recent meta-analysis highlighted several biologics that were associated with higher short-term and long-term PASI 75, PASI 90, and PASI 100 response rates.

Findings from a recent study showed an NK1 receptor antagonist may be an effective, new option for patients with psoriatic pruritus.

Psoriasis can affect patients at all walks of life, from children to the elderly. Adolescents, however, require special considerations, from psychosocial conditions to therapy options, for the short- and long-term management of psoriasis.